These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21295855)

  • 41. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
    Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
    Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Construction, expression and functional characterization of disulfide-stabilized anti-hepatocarcinoma single chain Fv fused with truncated Pseudomonas exotoxin].
    Zhao J; Sun ZW; Liu YF; Yu WY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Nov; 19(6):585-7. PubMed ID: 15182657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I; Pastan I
    Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
    Benhar I; Pastan I
    J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
    Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
    Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CCR9 and CCL25: A review of their roles in tumor promotion.
    Xu B; Deng C; Wu X; Ji T; Zhao L; Han Y; Yang W; Qi Y; Wang Z; Yang Z; Yang Y
    J Cell Physiol; 2020 Dec; 235(12):9121-9132. PubMed ID: 32401349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model.
    Hu CC; Ji HM; Chen SL; Zhang HW; Wang BQ; Zhou LY; Zhang ZP; Sun XL; Chen ZZ; Cai YQ; Qin LS; Lu L; Jiang XD; Xu RX; Ke YQ
    Int J Cancer; 2010 Nov; 127(9):2222-9. PubMed ID: 20127864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.
    Johnson-Holiday C; Singh R; Johnson EL; Grizzle WE; Lillard JW; Singh S
    World J Surg Oncol; 2011 May; 9():46. PubMed ID: 21539750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
    Kreitman RJ; Puri RK; Pastan I
    Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
    J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stealth and mimicry by deadly bacterial toxins.
    Yates SP; Jørgensen R; Andersen GR; Merrill AR
    Trends Biochem Sci; 2006 Feb; 31(2):123-33. PubMed ID: 16406634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
    Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
    J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of caspases in immunotoxin-induced apoptosis of cancer cells.
    Keppler-Hafkemeyer A; Brinkmann U; Pastan I
    Biochemistry; 1998 Dec; 37(48):16934-42. PubMed ID: 9836586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
    Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
    Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantification of immunotoxin number for complete therapeutic response.
    Kreitman RJ
    Methods Mol Biol; 2001; 166():111-23. PubMed ID: 11217362
    [No Abstract]   [Full Text] [Related]  

  • 57. Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism.
    Jenkins CE; Swiatoniowski A; Issekutz AC; Lin TJ
    J Biol Chem; 2004 Aug; 279(35):37201-7. PubMed ID: 15205454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGF ligand fused to truncated Pseudomonas aeruginosa exotoxin A specifically targets and inhibits EGFR‑positive cancer cells.
    Hashimi SM; Grant B; Alqurashi N; Alowaidi F; Wei MQ
    Oncol Rep; 2018 Nov; 40(5):2690-2697. PubMed ID: 30226622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.
    Kumar P; Kumar A; Parveen S; Murphy JR; Bishai W
    Immunotherapy; 2019 Sep; 11(13):1117-1128. PubMed ID: 31361167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis.
    Wurbel MA; Le Bras S; Ibourk M; Pardo M; McIntire MG; Coco D; Geha RS; Fiebiger E; Snapper SB
    Inflamm Bowel Dis; 2014 Jul; 20(7):1165-76. PubMed ID: 24874458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.